An integrated POC solution for diagnosis and therapy monitoring of Heart Failure patients

  • Logo 1
  • Logoe 2
You are here: Home / About

About

KardiaTool is a project funded by the European Union, with fourteen partners from nine European countries and one non-European country (United States). The consortium is composed of five Universities, five research centers, two SMEs and two industry partners. KardiaTool consortium join forces to translate a laboratory proven concept of a saliva biosensor to the clinical practice for addressing the priority needs in personalized HF diagnostics and therapy monitoring at the point of care.

The three-year and half project targets HF, a disease experienced globally by 26 million people with an annual cost to insurers estimated to be approximately 6.000€ per person. The recognition of non-adherent HF patients is important since, even if these patients are fortunate to have at their disposal a plethora of guidelines and health-based knowledge, the integration of this knowledge in their life becomes difficult. Furthermore, HF is associated with poor prognosis, increased mortality and morbidity and frequent re-hospitalizations that pose a great problem for both patients and their families, as well as, the healthcare system. As the overall life expectancy has increased, the global community is now facing new challenges of improving quality of life and healthcare at affordable costs.

KardiaTool will facilitate improved personalized healthcare for HF, through the transformation of the delivery of care, and provision of fast and accurate insights directly within the HF patient-care pathway. The integration of KardiaTool diagnostic and therapy monitoring platform into the patient-care pathway will provide the healthcare professionals with lab-quality results in less than an hour, will increase the patients' access to high-quality, efficient care, and improve the quality of care delivered to HF patients.